Thomas Pierret 🫁

#MD #pulmonologist #lungcancer

[Dr. Antonio Calles 🫁🚭 @Tony_Calles]

☢️ Concurrent thoracic radiotherapy + chemotherapy + durvalumab phase III trial in stage IV SCLC stopped early due to excess of deaths in the radiotherapy arm.
Not improvement in ORR, PFS, or OS but added toxicity to standard CASPIAN.
A definitively NOT TO DO. #ASCO26 #LCSM

[Stephen V Liu, MD @StephenVLiu]

Dr. @drshieldsmd gives a great discussion on SCLC at #ASCO26. Tarlatamab update shows the drug raises the bar but points out importance of ICANS awareness. Is it higher in its with brain metastases?

[Dr. Antonio Calles 🫁🚭 @Tony_Calles]

Tarlatamab continues to impress the oncology community with the CNS activity in relapsed ES-SCLC presented today.
🧠 Controlling not only previously treated brain metastases at baseline but also preventing them from appearing, while maintaining a better tox profile than chemotherapy, with the exception of disgeusia 👅 and increased ICANS
#ASCO26 #LCSM

[Uğur Özkerim @UOzkerim]

#ASCO26

One of the most clinically relevant SCLC updates of the meeting.

In DeLLphi-304, tarlatamab not only improved OS versus chemotherapy, but also showed meaningful intracranial activity:

• CNS progression/death HR 0.54 overall
• HR 0.40 in patients with brain metastases
• CNS CR 15% vs 5%

For a disease where brain progression remains a major challenge, these results matter
@OncoAlert @StephenVLiu @christine_lovly @GlopesMd @RManochakian @OncoReporte @MedwatchKate @weoncologists

[Dr Riyaz Shah @DrRiyazShah]

SYS6043 B7-H3 ADC ; B7-H3 expresssion levels didn’t correlate with response in lung. #ASCO26

[Alfredo Addeo MD @Alfdoc2]

#ASCO2026 | LORIN Phase II
Neoadjuvant lorlatinib in stage III ALK+ NSCLC delivered impressive results:
pCR 47%,MPR 81%,ORR 84%, 75% surgical conversion in initially unresectable disease
Small, single-arm study? Absolutely. Randomized confirmation needed? Of course.Practice changing? Debatable.
But if I see a stage III ALK+ patient tomorrow, these data would be very hard for me to ignore. I probably wouldn’t hesitate to discuss a neoadjuvant ALK-directed approach at the MDT.
#LungCancer #NSCLC #ALK #Lorlatinib #PrecisionOncology #ASCO26

[Hidehito HORINOUCHI @HHorinouchi]

🆙 #ASCO26 #LCSM Oral
🔥LORIN: Neoadj Lorlatinib in Stage III ALK+ NSCLC
✅ORR 83.7%, pCR 46.9%, MPR 81.3%
✅75% unresectable → conversion surgery
✅1y EFS 97.1%
🎙️Dr. Chao Zhang
🔢8002
☑️NCT05740943
🔗 https://t.co/ZCybx5kv9h
@OncoAlert @Larvol @ASCO @IASLC @ALKPositiveinc

[Hidehito HORINOUCHI @HHorinouchi]

🆙 #ASCO26 #LCSM Rapid Oral
🔥AEGEAN: TME Transcriptomic Analysis
✅3 clusters: C1 desert, C2 suppressed, C3 activated
✅Neoadj Durlva: C1 at surg 17.9% vs 47.2% (PBO); C3 EFS HR 0.16
🎙️Dr. John V. Heymach
🔢8015
☑️NCT03800134
🔗 https://t.co/AH7Kpjn2pT
@OncoAlert @Larvol @ASCO @IASLC

[Hidehito HORINOUCHI @HHorinouchi]

🆙 #ASCO26 #LCSM Rapid Oral
🔥Tumor-Naïve Multimodal MRD after Resection
✅Landmark MRD+: rec HR 9.72
✅Longitudinal MRD+: HR 16.64; lead time 264 days
✅Robust in all stages incl. stage I
🎙️Dr. Di Lu
🔢8016
🔗 https://t.co/VgIMK63lk5
@OncoAlert @Larvol @ASCO @IASLC #Liquidbiopsy

[Hidehito HORINOUCHI @HHorinouchi]

🆙 #ASCO26 #LCSM Rapid Oral
🔥TRACERx: Ultrasensitive Sub-10 PPM ctDNA MRDNSCLC
✅Post-op <10 PPM: RFS HR 3.49, OS HR 2.58 vs undetected
✅ctDNA preceded imag in 120 pts
🎙️Dr. Jonathan Wan
🔢8017
🔗 https://t.co/EutTJKfIX0
@OncoAlert @Larvol @ASCO @IASLC #Liquidbiopsy

[Hidehito HORINOUCHI @HHorinouchi]

🆙 #ASCO26 #LCSM Oral
🔥ALCHEMIST (EA5142): Adj Nivo after Surgery + Chemo in Resected NSCLC
✅DFS HR 0.97 (95%CI 0.81-1.17)
✅PD-L1 ≥50%: DFS HR 0.86 (95%CI 0.59-1.25)
🎙️ @ChaftJamie
🔢8000
☑️NCT02595944
🔗 https://t.co/EuJFpRMFGh
@OncoAlert @Larvol @ASCO @IASLC

[Veli Bakalov, MD @HemeOncBuddy]

TAXIO/IFCT-2203 (Abs 8091): paclitaxel/carbo/durva in 1L ES-SCLC.

👉ORR 82.4%,
👉12-mo OS 57.4%,
👉mOS 14.5 mo,
👉mPFS 4.6 mo.

Safety: grade 3-5 TRAEs 48.5%; 2 treatment-related sepsis deaths.

Bottom line: active + convenient one-day regimen, but toxicity is real and PFS does not scream “better than EP/IO.” would be nice especially for inpatients induction.

[Stephen V Liu, MD @StephenVLiu]

LIBRETTO 432 @NEJM after #ASCO26: phase III adjuvant selpercatinib vs placebo x 3y in pts w/ resected RET+ NSCLC (n=151). 2y EFS rate 92% vs 61% (HR 0.17). Most common AEs were LFT elevation. Fits established paradigm and sets a new standard of care.

https://t.co/5ie9KCePU7

[Urs Weber MD @UrsWeberMD]

Pumitamig, a novel PD-L1/VEGF-targeted bispecific antibody, shows encouraging efficacy in combination with chemotherapy as a 1st line treatment for NSCLC, even when PD-L1 expression is low. Responses appear to be durable, but longer term follow-up will be informative. #ASCO2026

[Tuğba Başoğlu, MD @tugbawitter]

#ASCO2026

PD-(L)1 × VEGF-A bispecifics are generating early excitement in NSCLC.

✅ Responses across squamous and non-squamous histologies
✅ Activity across PD-L1 subgroups
✅ Limited high-grade bleeding toxicity

Early data only—but a potentially important new direction in frontline immunotherapy.@OncoAlert @ozdogan_md

[Jordi Remon @JordiRemon]

1stL in KRASG12Cmut NSCLC will be crowded and complex. Elisrasib, another KRASG12Coff inh, reported activityn in 1stL alone and combo with pembro. Next future: how to decide intensification? Based on PDL1, comut, brain met status🤯.Will not be easy!! To icity is a concern #ASCO26

[Dr. Antonio Calles 🫁🚭 @Tony_Calles]

DZD6008, 4th-generation EGFR TKI with intracranial activity, showing 42% ORR in previously treated EGFR C797X+ lung cancer.
#ASCO26 #LCSM

[Hidehito HORINOUCHI @HHorinouchi]

🆙 Abstract #ASCO26 #LCSM Clinical Science Symp
🔥FLAME: Osimertinib ± CT in Persistent ctDNA EGFRm NSCLC at 3 Weeks after 1L Osimertinib
✅mPFS 23.1 vs 12.7mo (HR 0.53; 95%CI 0.31-0.92)
✅ORR 50 vs 35%; mDoR 15.6 vs 10.5m
🎙️Dr. Zhijie Wang
🔗 https://t.co/N5yLaYR8qt
@OncoAlert @Larvol @ASCO @IASLC @EGFRResisters #Liquidbiopsy

[Nurullah İlhan,MD @drnurullahilhan]

#ASCO26 TRITON IA results (T+D+CT vs P+CT in STK11/KEAP1/KRAS mutant non-squamous mNSCLC)
Key numbers:
• ORR: 39% vs 35% (no meaningful difference)
• 6-month response durability: 100% vs 58% → this is the intriguing signal
PFS still blinded, follow-up immature, safety looks good.
Not practice-changing yet, but the durability difference in this hard-to-treat population is worth watching closely.
Thoughts? Real biological effect or selection? Waiting for PFS/OS.
#LCSM #NSCLC #Immunotherapy #ASCO26
@GlopesMd @OncoAlert @StephenVLiu @Jani_Chinmay

https://t.co/TioPUVfIDa

[Elvina Almuradova @Dr_ElvinaA]

HR 0.28 in TPS 1-49% NSCLC sounds transformative. Until you notice the control arm is pembro mono, where chemo-immuno is standard. #ASCO26 #NSCLC @Larvol @OncoAlert @DrYukselUrun @weoncologists